NVO - Novo Nordisk

-

$undefined

N/A

(N/A)

Novo Nordisk NYSE:NVO Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Location: Novo Alle 1, Bagsvaerd, 2880, Denmark | Website: https://www.novonordisk.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

385.5B

Cash

41.55B

Avg Qtr Burn

N/A

Short % of Float

0.87%

Insider Ownership

0.01%

Institutional Own.

9.86%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Alhemo® (concizumab) Details
Hemophilia, Blood disorder

Approved

Quarterly sales

Once-weekly basal insulin icodec Details
Diabetes mellitus , Type 1 diabetes

BLA

Resubmission

Phase 3

Data readout

CagriSema Details
Obesity, Type 2 diabetes

Phase 3

Data readout

Phase 2/3

Update

FT-7051 (CBP/P300 inhibitor) Details
Castration-resistant prostate cancer

Failed

Discontinued